InspireMD, Inc. (NYSE:NSPR) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Sell” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
InspireMD, Inc. (NYSE:NSPR) lost -20 Percent and closed its previous trading session at $0.13. The stock traded with the average Volume of 1.72 Million at the end of last session.
InspireMD, Inc. (NYSE:NSPR) has the Market Capitalization of 1.28 Million. The Stock has its 52-week High of $3.970 and 52-Week Low of $0.020 and it touched its 52-week high on 01/10/17 and 52-Week Low on 12/06/17.
The company reported its last earnings Actual EPS of $-4.75/share. While, the analyst predicted that the company could provide an EPS of $-4.25/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.5/share which shows an Earnings Surprise of -11.8 Percent.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -63.56% where SMA50 and SMA200 are -66.61% and -79.3% respectively.
The company shows its Return on Assets (ROA) value of -98%. The Return on Equity (ROE) value stands at -165.5%. While it’s Return on Investment (ROI) value is -114.2%.
InspireMD, Inc. (NYSE:NSPR) currently has a Weekly Volatility of 24.58% percent while its Monthly Volatility is at 18.88% percent. While talking about Performance of the Stock, InspireMD, Inc. currently has a Weekly performance of -32.45%, monthly performance percentage is -66.93 percent, Quarterly performance is -59.54 percent, 6 months performance shows a percent value of -76.73% and Yearly Performance is -96.06 percent.
InspireMD Inc. is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard(TM). The Company’s initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. It focuses on applying its technology to develop additional products used for other vascular procedures, specifically carotid and peripheral procedures. InspireMD Inc. is headquartered in Tel Aviv, Israel.